Poor
Not Aligned
Patient Risk:
Moderate
Summary
Overall alignment is poor due to multiple claims being marked absent/unsupported without verifiable label support in the provided label excerpts, including an adverse-effect characterization (“common side effects include increased urination”) and several administration/missed-dose/timing-related claims marked absent. Several other safety-related counseling elements are directionally consistent with the label but the evaluation contains substantial unsupported/incorrect determinations.
Category Scores
Accurate Statements
Farxiga is the brand name for dapagliflozin.
11 DESCRIPTION
Dapagliflozin blocks sodium-glucose transporters in the kidney (SGLT2).
11 DESCRIPTION; 12.1 Mechanism of Action
Blocking SGLT2 promotes urinary glucose excretion.
12.1 Mechanism of Action; 5.3 Genitourinary Infections (increases urinary glucose excretion)
Dapagliflozin lowers blood glucose (in the context of glycemic control).
1 INDICATIONS AND USAGE (adjunct to diet and exercise to improve glycemic control); 12.1 Mechanism of Action
Dapagliflozin increases the risk of genitourinary infections including genital mycotic infections.
5.3 Genitourinary Infections...; 6 ADVERSE REACTIONS
Dapagliflozin can cause intravascular volume depletion, which may manifest as symptomatic hypotension and acute transient changes in creatinine.
5.2 Volume Depletion
Patients with a history of genitourinary infections are more likely to develop genitourinary infections when using FARXIGA.
5.3 Genitourinary Infections...
Precipitating conditions for ketoacidosis include reduced caloric intake and acute febrile illness.
5.1 Diabetic Ketoacidosis... (reduced caloric intake; acute febrile illness)
FARXIGA is prescribed once daily at 10 mg orally for other adult indications (as shown in the provided dosage section).
2.3 Recommended Dosage for Other Indications in Adults (10 mg orally once daily)
If a dose is missed, patients should not double up the next dose.
2.5 Recommendations Regarding Missed Dose; 17 Patient Counseling Information (Missed Dose)
Unsupported Statements
Common side effects of dapagliflozin include increased urination.
Not supported as stated as a “common side effect” in the provided label excerpts. The label discusses increased urinary glucose excretion and genitourinary infections, but the claim specifically asserts “common side effects include increased urination” without direct support in the excerpts.
Genital fungal infections are more frequent with SGLT2 inhibitors.
The provided label excerpts do not state comparative frequency of genital mycotic infections across SGLT2 inhibitors; they state risk with FARXIGA and mechanisms, not a comparative frequency statement.
The exact timing of Farxiga (morning vs. evening), whether it is taken with or without food, and dose adjustments depend on the condition being treated and kidney function.
The provided label excerpts do not support administration timing with respect to morning/evening or with/without food, nor the stated dependence pattern beyond what is explicitly shown.
If a dose is missed, patients generally follow prescription label directions or clinician guidance.
The provided label excerpts include missed-dose instructions, but the phrase “generally follow prescription label directions or clinician guidance” is not directly supported.
If a dose is missed, patients generally take it when remembered unless it is close to the next dose.
The provided label excerpt (2.5 and 17) states to take the dose as soon as possible and not double up, but it does not include the “unless it is close to the next dose” condition.
Alternatives to Farxiga may include dapagliflozin generics or other SGLT2 inhibitor brands.
Not supported within the provided label excerpts; this is outside the provided prescribing information scope.
Farxiga’s market exclusivity and patent landscape can shape when competitors may enter and how pricing evolves.
Not supported by the provided prescribing information; not a drug-label claim.
Contradictions
Important Omissions
Boxed warnings and contraindications were not addressed by the evaluated claims list.
Importance:
Moderate
Administration details beyond once-daily dosing (e.g., with/without food, specific timing rules) were not verifiably aligned to the label excerpts provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Adverse-effect characterization and missed-dose administration details include statements that are not supported by the provided label excerpts (e.g., “common side effects include increased urination” and missing-dose timing caveat), which could lead to inaccurate patient counseling. Several safety warnings (volume depletion/hypotension and ketoacidosis risk factors/monitoring) were directionally consistent.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported or not directly supported by the provided prescribing-information excerpts, including adverse-effect “commonness” and specific administration/missed-dose timing details.
Suggested Improvement
Limit claims to language directly supported by the provided label sections (e.g., use wording about increased urinary glucose excretion and genitourinary infections rather than “common increased urination”; for missed doses use “as soon as possible” and “do not double up” without adding unstated caveats; remove non-label market/patent/pricing claims).